CVALF (CVALF) Stock Price & Analysis
CVALF (CVALF) rose 8.02% to USD 2.56 as of September 8, 2026 at 22:51 UTC, according to Nexqual real-time market data.
CVALF last closed at USD 2.37; the session ranged USD 2.46–2.58 on volume of 4,901 shares. Market capitalization is $70.70M, with a 52-week range of USD 1.16–2.58 (OQX). Source: Nexqual, September 8, 2026 at 22:51 UTC.
Key Statistics (as of September 8, 2026 at 22:51 UTC)
| Price | USD 2.56 |
|---|---|
| Change | ▲ 8.02% (up) |
| Previous Close | USD 2.37 |
| Open | USD 2.46 |
| Day Range | USD 2.46 – 2.58 |
| 52-Week Range | USD 1.16 – 2.58 |
| Volume | 4,901 shares |
| Market Cap | $70.70M |
| Exchange | OQX |
Technical Analysis (CVALF)
Nexqual's technical model rates CVALF "BUY" based on 5 bullish and 3 bearish signals across 127 daily candles, as of September 8, 2026 at 22:51 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 92.26 (overbought) |
| vs SMA50 | Above (USD 1.68) |
| MACD | 0.2 (positive) |
Analyst Ratings (CVALF)
Wall Street analysts rate CVALF "Strong Buy", per Nexqual as of September 8, 2026 at 22:51 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Buy / Hold / Sell | 1 / 0 / 0 |
Earnings (CVALF)
| Next Earnings Date | 2026-08-27 |
|---|---|
| EPS Estimate | USD 0.04 |
| Revenue Estimate | $10.11M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 0.1 vs est 0.02 ▲ beat |
| 2026-03-31 | USD 0.04 vs est 0.02 ▲ beat |
| 2025-12-31 | USD 0.01 vs est 0.04 ▼ miss |
| 2025-09-30 | USD 0.01 vs est -0.04 ▲ beat |
Source: Nexqual, September 8, 2026 at 22:51 UTC.
Financials & Fundamentals (CVALF)
| Total Revenue | $34.35M |
|---|---|
| Revenue Growth (YoY) | +19.90% |
| Gross Margin | +59.87% |
| Operating Margin | +27.16% |
| Profit Margin | +12.78% |
| ROE | +14.33% |
| Debt / Equity | 5.35 |
| Current Ratio | 8.56 |
| Total Cash | $19.39M |
| Total Debt | $1.69M |
| Free Cash Flow | $2.94M |
Source: Nexqual, September 8, 2026 at 22:51 UTC.
Financial Health Score (CVALF)
Nexqual rates CVALF's overall financial health "Solid" across five dimensions, as of September 8, 2026 at 22:51 UTC.
| Growth | Solid — Revenue +5% YoY (annual) |
|---|---|
| Profitability | Weak — Small revenue base — building scale |
| Balance Sheet | Strong — $19M cash vs $2M debt, net cash position |
| Cash Flow | Solid — FCF $3M, 9% margin |
| Efficiency | Mixed — ROE 14%, ROA 6.9% |
Ownership (CVALF)
| Insider Ownership | +47.16% |
|---|---|
| Institutional Ownership | +0.00% |
| Shares Outstanding | 27.62M |
| Float | 14.94M |
Source: Nexqual, September 8, 2026 at 22:51 UTC.
Leadership (CVALF)
CVALF is led by Brent Ashton, CEO & Director, per Nexqual as of September 8, 2026 at 22:51 UTC.
| CEO & Director | Brent Ashton |
|---|---|
| Co-Founder, Chief Scientific Officer & VP | Valerio DiTizio (age 57) |
| Chief Financial Officer | Katie Martinovich |
| COO & Director | Kimberley Crooks |
| Vice President of Marketing | Kerri Kelley |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| MBXBF | MICROBIX BIOSYSTEMS | USD 0.23 | ▲ 5.07% |
| ACBM | ACRO BIOMEDICAL CO LTD | USD 0.03 | ▲ 0% |
| BIOAF | BIOASIS TECHNOLOGIES INC | USD 0 | ▲ 0% |
| MCUJF | Medicure Inc. | USD 1.88 | ▲ 5.03% |
| VIVXF | AVIVAGEN INC | USD 0 | ▲ 0% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 22:51 UTC. This page is informational and not investment advice.